The purpose of present study is to evaluate whether per-operative neoadjuvant therapy combined with surgery could improve the 1-year disease-free survival of stage III hepatocellular carcinoma patients.

Inclusion Criteria:

• Age 18-80 years old, both gender
• Confirmed diagnosis of stage III hepatocellular carcinoma(HCC)
• Fulfill the criteria of surgery
• No other severe comorbidity
• Eastern Cooperative Oncology Group score(ECOG) 0-2
• Expected survival > 3months
• Informed consent obtained.

Exclusion Criteria:

• Received chemoradiotherapy or other antineoplastic drugs
• Severe cirrhosis with Child-Pugh score >10
• Total bilirubin > 1.5 times upper limit, AST or ALT > 2times upper limit, indocyanine green retention rate after 15 min(ICG15) >=40%;
• Not fulfill the surgery criteria
• Received major surgery within 1month
• History of other tumor
• Participate other clinical trial within 1month
• Drug or alcohol abuse, AIDS
• Uncontrollable epileptic seizure or cognitive disorder
• Severe allergy
• Other unsuitable conditions.